Beverly Sha to Anti-HIV Agents
This is a "connection" page, showing publications Beverly Sha has written about Anti-HIV Agents.
Connection Strength
1.961
-
Enhanced inpatient rounds, appointment reminders, and patient education improved HIV care engagement following hospital discharge. Int J STD AIDS. 2018 06; 29(7):641-649.
Score: 0.578
-
Effectiveness of an electronic health record model for HIV pre-exposure prophylaxis. Int J STD AIDS. 2022 04; 33(5):499-502.
Score: 0.192
-
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 2000 Dec 06; 284(21):2723.
Score: 0.176
-
Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy. AIDS. 2000 Jul 07; 14(10):1470-1.
Score: 0.171
-
Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels. AIDS. 2000 Apr 14; 14(6):746-8.
Score: 0.168
-
Implementing Rapid Initiation of Antiretroviral Therapy for Acute HIV Infection Within a Routine Testing and Linkage to Care Program in Chicago. J Int Assoc Provid AIDS Care. 2020 Jan-Dec; 19:2325958220939754.
Score: 0.165
-
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500?000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019 05 01; 74(5):1376-1380.
Score: 0.157
-
Evaluation of pharmacy-implemented medication reconciliation directed at antiretroviral therapy in hospitalized HIV/AIDS patients. Ann Pharmacother. 2010 Jan; 44(1):222-3.
Score: 0.082
-
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J Interferon Cytokine Res. 2008 Feb; 28(2):89-100.
Score: 0.072
-
Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Feb 01; 35(2):120-5.
Score: 0.055
-
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.
Score: 0.054
-
CD32 is enriched on CD4dimCD8bright T cells. PLoS One. 2020; 15(9):e0239157.
Score: 0.043
-
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 05 17; 66(11):1689-1697.
Score: 0.037
-
Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS. 1999 May 28; 13(8):919-25.
Score: 0.010